Latest Period
Q2 2026
Security Snapshot
Transcode Therapeutics, Inc. - Common Stock (RNAZ) Institutional Ownership
CUSIP: 89357L501
13F Institutional Holders and Ownership History from Q2 2025 to Q2 2026
Institutions Reporting
8
Shares (Excl. Options)
33,504
Price
$6.21
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock
- Symbol
- RNAZ on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 33,504
- Total 13F value
- $208,059
- Portfolio coverage rank
- 0%
- Share change
- +2,647
- Value change
- -$14,137
- Number of holders
- 8
- Shares outstanding
- 16,846,819
- SEC-reported price per share
- $8.44
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
2 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- RNAZ - Transcode Therapeutics, Inc. - Common Stock is tracked under CUSIP 89357L501.
- 8 institutions reported positions in Q2 2026.
- 6 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 7 to 8 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $265,677 to $208,059.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 8 institutions filings for Q2 2026.
Security key
89357L501
Latest holder period
Q2 2026
13F holders
8
13D/G owners
6
CIK / CUSIP context first
Open Q2 2026 holders
RNAZ full holder history
Transcode Therapeutics, Inc. SEC filings
Transcode Therapeutics, Inc. company facts
Transcode Therapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 89357L501:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
6
Security
RNAZ
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| CK Life Sciences Intl (Holdings) Inc | 84% | 0% | $119,295,020 | 14,134,481 | 0% | CK Life Sciences Int'l., (Holdings) Inc. | 03 Aug 2026 | |
| Unleash Immuno Oncolytics, Inc. | 9.9% | $1,875,000 | 300,000 | Unleash Immuno Oncolytics, Inc. | 23 Jul 2026 | |||
| Braci Elena Rosa | 6.2% | $1,163,975 | 186,236 | Elena Rosa Braci | 23 Jul 2026 | |||
| Katzman Daniel Eduardo | 5.2% | $972,569 | 155,611 | Daniel Eduardo Katzman | 23 Jul 2026 | |||
| SABBY MANAGEMENT, LLC | 4.9% | $433,482 | 41,601 | SABBY MANAGEMENT, LLC | 31 Dec 2025 | |||
| GOLDMAN SACHS GROUP INC | 0% | -98% | $882 | -$526,307 | 82 | -100% | THE GOLDMAN SACHS GROUP, INC. | 30 Sep 2025 |
As of 30 Jun 2026, 8 institutional investors reported holding 33,504 shares of Transcode Therapeutics, Inc. - Common Stock (RNAZ). This represents 0.2% of the company’s total 16,846,819 outstanding shares.
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
5
Latest
Q2 2026
Rows shown
1-5 of 5